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Abstract
Multiple genome-wide studies have identified associations between outcome of HIV infection and 
polymorphisms in/around the gene encoding the HIV co-receptor CCR5, but the functional basis 
for the strongest of these associations, rs1015164 A/G, is unknown. We found that rs1015164, 
located 34KB downstream of CCR5, marks variation in an ATF1 binding site that controls 
expression of the antisense long non-coding RNA CCR5AS. Knockdown or enhancement of 
CCR5AS expression resulted in a corresponding change in CCR5 expression on CD4+ T cells. 
CCR5AS interfered with interactions between the RNA-binding protein Raly and the CCR5 3’ 
untranslated region, protecting CCR5 mRNA from Raly-mediated degradation. Reduction in 
CCR5 expression through inhibition of CCR5AS diminished infection of CD4+ T cells with 
CCR5-tropic HIV in vitro. These data represent a rare determination of the functional importance 
of a genome-wide disease association where expression of a long non-coding RNA affects level of 
HIV infection and disease progression.
Introduction
The non-coding RNAs are classified either as small (<200 bp) or long (>200 bp) transcripts 
without protein coding potential. Long non-coding RNA (lncRNA) genes are numerous, 
exceeding the number of protein-coding genes, and are emerging as epigenetic regulators 
with a prominent role in health and disease. LncRNAs regulate gene expression, chromatin 
organization, cellular trafficking, RNA decay, and translation. Notably, the localization, 
function, decay, and turnover of proteins are also influenced by lncRNAs (reviewed in1). In 
several viral infections, cellular lncRNAs have been shown to regulate viral replication2, or 
cellular metabolic3 and immune responses4.
A large number of intergenic single nucleotide polymorphisms (SNPs) associate with human 
disease outcomes (GWAS catalog; http://www.ebi.ac.uk/gwas), many of which are in or near 
lncRNA genes and may mark differential expression or function of the lncRNAs5. Recently, 
the influence of some of these SNPs on expression or function of lncRNA genes, their 
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protein coding targets, and/or disease outcomes has been demonstrated in cancer6, the 
chronic immune-mediated disorder celiac disease7, and pneumococcal bacteremia8, but any 
potential role of lncRNA polymorphisms in viral infections remains uncharacterized.
Human chromosome 3p21–22 harbors a cluster of chemokine receptor genes, several of 
which can serve as co-receptors for HIV-19. CCR5 is the major co-receptor of HIV and 
variation in its expression influences the outcome of HIV-1 infection. Complete loss of 
CCR5 surface expression due to homozygosity for a 32-base pair (bp) deletion in CCR5 
(CCR5-Δ32) results in resistance to HIV infection10, 11. There is a decrease in CCR5 surface 
expression on T cells among CCR5-Δ32 heterozygous subjects compared to those carrying 
two functional copies of the gene12, 13. Additional SNPs and haplotypes have been shown to 
associate with CCR5 transcription, surface expression levels, and HIV-1 
susceptibility14, 15, 16, 17, 18. CCR5 surface expression levels influence multiple aspects of 
HIV pathogenesis and disease outcomes, such as HIV entry12, 13, viral load19, progression to 
AIDS19, neutralizing activity of HIV-1-specific antibodies20, immune reconstitution during 
highly active antiretroviral therapy19, 21, and the treatment efficacy of CCR5 blockers and 
entry inhibitors22, where in each instance, low CCR5 surface expression is protective. 
Genetic associations of CCR5 and CCR2 gene polymorphisms with HIV-1 pathogenesis are 
well established16, 23, 24, 25, including an intergenic SNP (rs1015164 A/G) downstream of 
the CCRL2 gene, which showed genome-wide significant association with HIV infection 
outcomes in meta-analyses that collectively examined genotyping data from 6,315 HIV-1-
infected patients26. The rs1015164 SNP was found to have a genome-wide effect 
independent of other SNPs in the region, including CCR5-Δ32, after correction for ethnicity, 
gender and cohort (p = 1.5×10−19). Here we show that this SNP is in close genomic 
proximity to RP-11–24F11.2, an anti-sense non-coding RNA gene that overlaps with CCR5, 
and marks expression of the transcript encoded by the gene. We termed this novel transcript 
CCR5AS. Our data reveal that higher expression levels of CCR5AS, as a consequence of a 
variant in an ATF1 transcription factor binding site that rs1015164A marks, enhance CCR5 
mRNA stability thereby increasing CCR5 mRNA and cell surface expression, and providing 
the functional basis for the association between rs1015164A and lack of HIV control.
Results
The rs1015164 SNP associates with HIV outcome after infection
The CCR5Δ32 mutation is present almost exclusively in people of European descent and 
confers nearly complete protection from HIV infection in homozygotes and slower 
progression to AIDS in heterozygotes for the mutation10, 11. Other CCR5 variants that 
associate with outcome to HIV infection, including rs1015164, however, are present across 
many populations, and some of these affect CCR5 expression13, 27, 28, 29. Among 2,745 
quantitative trait loci in a monocyte transcriptome-wide scan, rs1015164 was identified as a 
marker of CCR5 mRNA expression30. We tested for an effect of rs1015164 on viral load 
after HIV-1 infection in three ethnic groups: African Americans, Hispanics, and Japanese. 
Although the rs1015164A allele was less frequent in the African American and Hispanic 
cohorts, and homozygous individuals were rare, patients carrying at least one rs1015164A 
allele (AA+AG) had significantly higher viral load (increase of 0.24 log10 copies/ml for 
Kulkarni et al. Page 3
Nat Immunol. Author manuscript; available in PMC 2019 December 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
AA/AG, PAfrican American = 1.7×10−9; increase of 0.58 log10 copies/ml for AA/AG, PHispanic 
= 9.0×10−32; Fig. 1a, b) and decreased CD4+ T cell counts (−67.1 cells/μl for AA/AG, 
PAfrican American = 7.3×10−9; −121.7 cells/μl for AA/AG, PHispanic = 1.3×10−11; Fig. 1c, d) 
over time. These results extend the effect of rs1015164 beyond people of European descent 
as reported previously26, to Hispanics and African Americans. The rs1015164A allele was 
also less frequent in a sampling of Japanese patients compared to Europeans (Supplementary 
Fig. 1a); nevertheless, the AA genotype was significantly associated with higher viral loads 
in these patients (Supplementary Fig. 1b), pointing to a uniform deleterious effect of 
rs1015164A in HIV-1 infection across distinct populations. The consistency of the 
rs1015164 effect across the populations tested speak to a single functional mechanism 
explaining these associations.
rs1015164 marks expression of a novel lncRNA, CCR5AS
The rs1015164 SNP maps to the 5’ upstream region of a non-coding RNA gene RP-11–
24F11.2 (Fig. 2a), so we tested whether this gene was transcribed. We detected and 
quantified a lncRNA transcript in total RNA from peripheral blood lymphocytes (PBLs) by 
qPCR using RP-11–24F11.2-specific primers as confirmed by sequencing of the amplicons. 
Because the non-coding RNA is transcribed from the anti-sense strand of the CCR5 gene, 
the lncRNA transcript was termed CCR5AS. The rs1015164A allele, which we found (Fig. 
1) and was previously found to associate with higher viral loads26, associated with higher 
expression levels of CCR5AS in PBLs (Fig. 2b). As the primary cellular targets for HIV are 
CD4+ T cells, we tested and observed an association of rs1015164 genotype with CCR5AS 
expression levels in this cell type specifically, as well (Fig. 2c). In addition, rs1015164 
genotype showed a significant correlation with CCR5 cell surface expression in bulk 
memory CD4+ T cells (p = 0.02, Fig. 2d, Supplementary Fig. 2a), and effector memory 
CD4+ T cells (p = 0.02, Fig. 2d, Supplementary Fig. 2a). The rs1015164 SNP also marks 
expression of CCR5AS (ENSG00000223552.1) in whole blood, colon, visceral adipose, 
heart, brain, subcutaneous adipose and lung tissue (https://www.gtexportal.org/; 
Supplementary Fig. 2b).
Amplification of the 3’ and 5’ ends of the CCR5AS transcript uncovered the presence of two 
different isoforms, which are identical at the 5’ end. The short isoform lacks exon 2 and has 
a truncated exon 4 (Supplementary Fig. 2c). Both isoforms are more abundant in the 
cytoplasmic, relative to nuclear, RNA fractions from CD4+ T cells and the Hut-78 human T 
cell lymphoma cell line, both of which express CCR5 and CCR5AS (Supplementary Fig. 
2d). While the transcript did not contain any open reading frames longer than 20 codons, 
studies have suggested that several lncRNAs may in fact encode short peptides31. To test this 
possibility, we analyzed the CCR5AS transcript sequence using phyloCSF (phylogenetic 
codon substitution frequency)32, a conservation-based method that estimates whether a 
multispecies nucleotide sequence alignment in a specific locus is more likely to represent a 
protein coding than a non-coding transcript. The low phyloCSF score (−98.7) of CCR5AS is 
in line with that of other known non-coding RNAs than it is with that of known protein 
coding transcripts. No coding potential is predicted for the transcript by other methods such 
as RNAcode, coding potential assessment tool (CPAT), small ORF riboseq coding (http://
fantom.gsc.riken.jp/cat/ )33.
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CCR5AS enhances expression of the HIV co-receptor CCR5
LncRNAs can affect the expression of nearby genes (reviewed in34). Given that the CCR5 
gene is completely encompassed within the locus encoding CCR5AS (intron 2 specifically; 
Fig. 2a), we tested whether CCR5AS may be involved in differential expression of CCR5. 
Only a proportion of peripheral blood CD4+ T cells express CCR535. Nevertheless, 
CCR5AS expression levels in CD4+ T cells showed a significant, though moderate, positive 
correlation with levels of CCR5 mRNA expression (r=0.42, p=0.0001; Fig. 3a). Stronger 
correlations between CCR5AS and CCR5 mRNA levels were observed in peripheral 
memory CD4+ T cells and monocytes (r=0.72, p=0.0001 and r=0.82, p=0.0001, respectively; 
Fig. 3b, c), a larger proportion of which are known to express CCR535. Two distinct short 
interfering RNAs (siRNA) were used to silence CCR5AS expression (Supplementary Fig. 
3a, b). The siRNA-mediated knockdown of CCR5AS resulted in reduced mRNA and surface 
expression of CCR5 (Fig. 3d, e; Supplementary Fig. 3c, d), whereas overexpression of the 
CCR5AS short form increased mRNA and surface expression of CCR5 in primary CD4+ T 
cells (Fig. 3f, g), as did overexpression of the CCR5AS long form (Supplementary Fig. 3e, 
f). Taken together, these data indicate that CCR5AS might function as a regulator of CCR5 
expression levels. Since siRNA-mediated downregulation of CCR5AS also reduced mRNA 
and cell surface expression of CCR5 in the Hut-78 T cell line (Supplementary Fig. 4a, b), 
Hut-78 cells were used to further probe the molecular mechanism of CCR5AS-mediated 
regulation of CCR5.
Binding of the CCR5AS transcript to Raly protects CCR5 mRNA from degradation
Cytoplasmic lncRNAs have been shown to affect expression of their targets post-
transcriptionally (reviewed in36). We assessed the effect of CCR5AS knockdown on cellular 
CCR5 mRNA by estimating the decay rates of metabolically labeled CCR5 mRNA in 
Hut-78 cells treated with control siRNA (siCon1) or CCR5AS-targeting siRNA (siLnc1). 
The decay of CCR5 mRNA was significantly faster in siLnc1 treated cells (Supplementary 
Fig. 4c), indicating that silencing of CCR5AS results in degradation of CCR5 mRNA.
Cytoplasmic lncRNAs can function as sponges of microRNAs (miRNAs) and rescue 
expression of the miRNA targets. CCR5AS and CCR5 transcripts share binding sites for two 
miRNA (miR-197 and miR-1224), but in vitro transcribed CCR5AS lncRNA with mutations 
in the binding sites of either or both of these miRNAs still enhanced CCR5 mRNA 
expression (Supplementary Fig. 5), indicating that CCR5AS-mediated regulation of CCR5 
expression is independent of the shared miRNA binding sites.
There are several examples of lncRNAs that alter gene expression via the recruitment or 
sequestration of proteins involved in post-transcriptional regulation of translation37 or 
mRNA stability38, 39, 40. In order to determine the protein binding partners of CCR5AS 
lncRNA, we carried out RNA antisense purification (RAP) using a CCR5AS-specific probe 
that enriched CCR5AS transcript 1000 fold (Fig. 4a). The proteins pulled down were 
separated by polyacrylamide gel electrophoresis (PAGE), and prominent bands with 
differential intensity were analyzed by mass-spectrometry (MS) to identify the proteins that 
bound specifically to CCR5AS (Fig. 4b). The Raly RNA binding protein was identified 
specifically in the CCR5AS-specific (AS) pulldown, but not the scrambled control (SC) 
Kulkarni et al. Page 5
Nat Immunol. Author manuscript; available in PMC 2019 December 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
pulldown (Fig. 4c), a finding that was further confirmed in an antisense pull-down using 
immunoblotting (Supplementary Fig. 6a). In silico analysis also showed strong prediction of 
Raly binding to both isoforms of CCR5AS (Supplementary Fig. 6b). To confirm the 
endogenous CCR5AS interaction with Raly, we performed RNA immunoprecipitation 
(RIP), in which a version of Raly protein tagged with Myc at the C-terminal end of the 
protein coding sequence was overexpressed. Myc-tagged proteins were immunoprecipitated 
using anti-Myc antibody-coated magnetic beads, and immunoprecipitation of Raly protein 
was confirmed by Western blot (Supplementary Fig. 6c). Protein-bound RNA was analyzed 
by qPCR, showing that endogenous CCR5AS was enriched significantly in the Raly Myc-
pulldown (Raly-IP) as compared to control IgG coated beads (IgG-IP; Fig. 4d). These results 
indicate that CCR5AS RNA interacts with Raly.
Given the interaction between Raly and CCR5AS, we tested for an effect of Raly on CCR5 
expression level. Knockdown of Raly using a Raly-targeting siRNA (siRaly) was confirmed 
by immunoblot (Supplementary Fig. 6d). The suppressive effect of Raly on CCR5 
expression was evident by enhanced mRNA expression and surface expression of CCR5 72 
hours after siRNA mediated knockdown of Raly protein (Fig. 5a,b), a finding that was 
concordant with in silico analysis that strongly predicted binding of Raly to CCR5 3’UTR 
(Fig. 5c). These findings were further supported by cloning the CCR5 3’UTR region 
downstream of Renilla luciferase in a dual luciferase vector psicheck2 (Supplementary Fig. 
6e), transfecting the construct into Raly-inhibited cells, and testing the effect of Raly 
inhibition on luciferase reporter activity. The siRNA mediated knockdown of Raly protein 
increased the luciferase activity of the CCR5 3’UTR construct as compared to that in the 
control siRNA transfected cells (Fig. 5d). Thus, depletion of Raly enhances CCR5 
expression.
We hypothesized that CCR5AS may enhance stability of CCR5 mRNA by sequestering 
Raly, thereby keeping it from binding to the CCR5 3’UTR and degrading CCR5 transcripts. 
We tested directly whether the interaction between CCR5AS and Raly interferes with 
binding of Raly to the CCR5 3’UTR using Hut-78 cells transfected with Myc-tagged Raly 
plus either siLnc1 (to knockdown CCR5AS mRNA) or the control siCon1. Pulldown of 
Myc-tagged Raly protein from cellular lysates (input) by immunoprecipitation with anti-
Myc antibody (Raly-IP), but not control IgG (IgG-IP), was confirmed by Western blot 
(Supplementary Fig. 6f). Changes in the association between Raly and CCR5 3’UTR with or 
without silencing of CCR5AS were then measured by RIP. Enrichment of CCR5AS and 
CCR5 3’UTR in the Raly-bound RNA was estimated by qPCR. CCR5AS was found to be 
highly enriched in Raly pulldown from the siCon1 treated cells, but absent in Raly pulldown 
from the siLnc1 transfected cells in which CCR5AS was silenced (Supplementary Fig. 6g). 
As predicted by in silico analysis (Fig. 5c), CCR5 3’UTR was also found to be enriched in 
the Raly pulldown in siCon1 treated cells; however, association between the CCR5 3’UTR 
and Raly was significantly enhanced upon CCR5AS knockdown (Fig. 6a). Further, 
transfection of Hut-78 cells with vector containing the CCR5 3’UTR region downstream of 
Renilla luciferase (Supplementary Fig. 6e), followed by CCR5AS knockdown, resulted in 
diminished luciferase activity of the CCR5 3’UTR construct as compared to the control cells 
(Fig. 6b). We assessed the effect of Raly knockdown on cellular CCR5 mRNA stability by 
estimating the decay rates of metabolically labeled CCR5 mRNA in cells treated with 
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control siRNA (siCon) or Raly-targeting siRNA (siRaly). The decay of CCR5 mRNA was 
significantly slower in siRaly treated cells (Supplementary Fig. 6h), indicating that silencing 
of Raly results in increased stability of CCR5 mRNA. Overall, the data indicate that 
CCR5AS interferes with binding of Raly to the CCR5 3’UTR (Fig. 6c), thereby enhancing 
CCR5 mRNA stability.
Knockdown of CCR5AS reduces the susceptibility of CD4+ T cells to HIV-1 infection
The potential impact of CCR5AS-mediated regulation of CCR5 expression levels on HIV 
infection of CD4+ T cells was tested using an in vitro infection assay in which purified 
CD4+ T cells were transfected with siRNA to downregulate CCR5AS (siLnc1) or with 
control siRNA (siCon1). The CCR5AS siRNA transfected cells were infected with R5-tropic 
(CCR5 dependent) or VSV-G pseudotyped (CCR5 independent) HIV-1 vectors encoding a 
green fluorescent protein (GFP). The proportions of GFP+ cells in the siLnc1 treated cells 
were compared to that of the siCon1 treated cells. The siRNA-mediated silencing of 
CCR5AS led to 25–50% reduction in the proportion of GFP+ T cells in the cultures infected 
with the R5-tropic virus, whereas downregulation of CCR5AS did not affect the proportion 
of GFP+ cells in the cultures infected with the CCR5-independent VSV-G pseudotyped 
vector (Fig. 7a; Supplementary Fig. 7a-f). Similarly, primary CD4+ T cells from 
rs1015164AA/AG donors showed a significant increase in infection with R5-tropic virus as 
compared to CD4+ T cells from donors with the rs1015164GG genotype (p=0.02; Fig. 7b; 
Supplementary Fig. 7b-d), but there was no difference in infection with the VSV-G 
pseudotyped vector in donors with these rs1015164 genotypes. These data indicate that 
silencing of CCR5AS reduces infection of T cells with a CCR5-dependent virus.
Our results suggest that the rs1015164A allele marks high CCR5AS expression. High 
CCR5AS enhances CCR5 expression post-transcriptionally by sequestering the RNA 
binding protein (RBP) Raly from the CCR5 3’UTR, and thereby protecting CCR5 mRNA 
from Raly-mediated decay, resulting in higher surface expression of CCR5, enhanced HIV 
infection, and higher HIV-1 viral loads (Supplementary Fig. 8).
rs2027820 is in perfect linkage disequilibrium with rs1015164, and influences the binding 
of activating transcription factor 1 (ATF1)
Bioinformatic analysis indicated that the rs1015164 SNP does not appear to be in a 
transcription factor binding site. There are, however, additional SNPs located upstream of 
CCR5AS (rs35937775) and in the intronic regions of CCR5AS (rs6441975, rs2027820, 
rs2373232) that are in perfect/near perfect linkage disequilibrium (LD) (r2=0.9–1) with 
rs1015164 in Europeans, Japanese and Africans (http://www.internationalgenome.org). Only 
one of these four SNPs, rs2027820, which is located in the first intron of CCR5AS, was 
predicted to lie within a transcription factor binding site and alter binding potential. The 
minor allele rs2027820G (in LD with rs1015164A, which associates with higher CCR5AS 
expression levels; r2=1 in Europeans and Africans, r2=0.94 in Japanese) maintains an intact 
binding site for ATF141, and is therefore predicted to enhance CCR5AS expression, whereas 
the major allele, rs2027820A (in LD with rs1015164G), disrupts the binding site. The 
presence of an ATF1 binding site within a sequence containing the rs2027820G variant was 
confirmed by electrophoretic mobility shift assay (EMSA) using rs2027820G vs. A 
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oligonucleotides (Fig. 8a). As predicted, the A variant had greatly diminished binding 
compared to the G variant using Jurkat and HeLa nuclear extracts, as well as nuclear extracts 
from HEK 293 cells transfected with ATF1. We further tested the enhancer effect of the 
rs2027820 alleles using a luciferase reporter construct. A 1000 base pair fragment 
immediately upstream of the transcription start site of CCR5AS and a 500 base pair intronic 
fragment containing the rs2027820A/G polymorphic site were cloned upstream and 
downstream of the firefly luciferase gene, respectively (Fig. 8b). Relative luciferase activity 
of the construct containing rs2027820G (intact ATF1 binding site) was significantly higher 
as compared to the construct containing rs2027820A (disrupted ATF1 binding site) (Fig. 8c). 
These data support a model in which the CCR5AS intronic rs2027820 variant, which is in 
virtually perfect LD with rs1015164, regulates expression of CCR5AS through differential 
binding of ATF1.
Discussion
The chemokine receptor gene cluster on human chromosome 3 encodes co-receptors for 
HIV-1, including the major co-receptor CCR5. Multiple independent candidate gene 
approaches and subsequent genome-wide studies have identified clear associations between 
polymorphisms within/near to CCR5, most prominently the CCR5Δ32 mutation, and 
outcomes of HIV infection. Reduction or absence of CCR5 expression due to heterozygosity 
or homozygosity for CCR5Δ32, respectively, also associates with HBV recovery42, whereas 
increased risk of fatal West Nile Virus infection associates with homozygosity for this 
mutation43, indicating the general importance of CCR5 expression levels in the immune 
response to viral infection. The work presented here demonstrates a novel mechanism of 
differential CCR5 regulation through the expression level of a lncRNA, CCR5AS. Our 
results reveal that a variant located upstream of CCR5AS, rs1015164A/G, associates with 
CCR5AS expression. High expression of CCR5AS (marked by rs1015164A) enhances 
CCR5 expression post-transcriptionally by sequestering the RBP Raly, inhibiting the binding 
of Raly to the CCR5 3’UTR, and thereby protecting CCR5 mRNA from Raly-mediated 
decay. Interestingly, the CCR5AS lncRNA sequence, as well as its genomic position with 
respect to the CCR5 gene, are conserved in non-human primates, raising the possibility that 
its regulatory function may also be conserved.
The rs1015164A/G variant has been shown to have a genome-wide significant effect on HIV 
infection outcomes in people of European ancestry, and its effect is independent of CCR5-
Δ32 and other polymorphisms in the region26. We extend these studies showing a deleterious 
effect of rs1015164A in untreated HIV-1 infected African Americans, Hispanics and 
Japanese, in whom the CCR5-Δ32 mutation is virtually absent. Thus, differential CCR5AS 
expression may be the primary means for regulating CCR5 expression levels worldwide. 
Although CCR5 is not a receptor for HBV, CCR5-Δ32 has been shown to associate with 
spontaneous recovery of HBV42, apparently through immunological mechanisms44, 45. The 
rs1015164 genotype may also associate with outcome after HBV infection in a manner 
consistent with lower CCR5 expression (i.e. rs1015164G) conferring protection, as we 
observed a trend towards enhanced HBV recovery with increasing copy number of 
rs1015164G (p for trend = 0.04; data not shown). These data suggest a general importance 
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of CCR5 expression levels and the mechanisms responsible for this differential regulation in 
diseases where CCR5 contributes to viral entry and/or the immune response.
The rs1015164 SNP is intergenic and is not predicted to be located in a transcription factor 
binding site; therefore, it is unlikely to be directly responsible for differential CCR5AS 
expression levels. However, a variant located in the first intron of CCR5AS, rs2027820, may 
directly affect expression levels of this gene, as it is located within a binding site for the 
transcription factor ATF1 and it is in virtually perfect LD with rs1015164. ATF1 belongs to 
the cAMP-regulated enhancer-binding (CREB) family of transcription factors and is 
expressed in a wide variety of cell types41. We show that rs2027820G, which is in LD with 
rs1015164A, allows binding of ATF1 and enhances protein expression in a luciferase assay 
relative to rs2027820A, indicating that the rs2027820G variant enhances CCR5AS 
expression levels, whereas the A variant confers poor binding of ATF1 and relatively poor 
expression of CCR5AS.
The majority of lncRNAs are in low abundance and localize to the nucleus, where they 
participate in transcriptional regulation through diverse mechanisms (reviewed in46). 
However, some localize to the cytoplasm, which we have observed for CCR5AS. While 
cytoplasmic lncRNAs can modulate mRNA stability or translation (reviewed in36, 47) by 
directly binding to their mRNA targets, others harbor miRNA binding sites that are in 
common with those present in the protein coding mRNA targets of the miRNAs. This 
competitive sequestration or “sponging” of the miRNAs protects the protein coding mRNA 
targets from miRNA-mediated repression. Similarly, lncRNAs can serve as ‘decoys’ of 
RBPs, sequestering RBPs from mRNA, and thereby regulating mRNA splicing, decay or 
translation. LncRNA mediated modulation of the molecular and spatial availability of RBPs 
has been shown to affect cell cycle, transformation, differentiation and the immune response. 
We showed that CCR5AS behaves as a decoy for the RBP Raly, preventing its binding to 
and repression of CCR5 such that the expression levels of these two RNA species are 
positively correlated.
Surveys of published GWAS show that most disease or trait-associated polymorphisms 
occur in non-coding regions48 with an enrichment in regulatory elements or expression 
quantitative trait loci (eQTL)49, suggesting that the basis for these disease associations are 
due in part to regulation of gene expression. Only 3% of the entire transcriptome is protein-
coding50, signifying the vast predominance of non-coding RNAs in the human 
transcriptome. Thus, it is possible that a sizable portion of previously identified intergenic 
GWAS SNPs could be marking variation in function or expression of non-coding RNAs.
The functional explanations for the vast majority of disease-associated SNPs identified by 
GWAS remain unknown. Here we provide the underlying biological basis for the genome-
wide association between the rs1015164A/G variant and outcome after HIV infection, 
establishing a foundation for potential therapeutic interventions.
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Methods
Samples
Healthy European American (EA) donors recruited at the National Cancer Institute, 
Frederick, MD were used for determination of rs1015164 genotypes and the characterization 
of CCR5AS expression and transcript sequence. Data from a total of 1323 HIV-1-infected 
individuals (African American = 992, Hispanics = 331), were used in this study. The 
subjects in this study were enrolled into one of six cohorts: the AIDS linked to the 
Intravenous Experience (ALIVE) 51, the Massachusetts General Hospital controller cohort 
(MGHCC) (http://www.hivcontrollers.org/hivcontrollers), the Study on the Consequences of 
Protease Inhibitor Era (SCOPE) 52, the AIDS Clinical Trial Group cohort (ACTG) (https://
actgnetwork.org), the U.S. military HIV Natural History Study (USMNHS) 
(www.idcrp.org), and the Multicenter AIDS Cohort Study (MACS). Five hundred and four 
chronically HIV-1 subtype B-infected, ART-naïve Japanese individuals (464 men and 40 
women) were recruited in the National Center for Global Health and Medicine during 2000–
201053. The respective institutional review boards approved the study, and all subjects gave 
written informed consent.
rs1015164 genotyping
DNA samples were amplified from genomic DNA by PCR using specific primers for the 
200bp flanking rs1015164. The amplicons were sequenced in both directions with the same 
primers using an ABI-31730XL DNA analyzer (Applied Biosystems).
Statistical Analyses
Analysis of the log10 transformed HIV VL and CD4+ T-cell count at each timepoint was 
performed with the lmer function in R and presence of CCR5Δ32 was used as a covariate. 
We allowed for random effects due to the time post enrolment. Likelihood ratio p-values 
using the ANOVA function in R were calculated to compare nested models fit under a 
maximum-likelihood scenario. The p values for the effect of rs1015164 genotype on HIV-1 
viral load in the Japanese cohort were generated by the Mann-Whitney U test. SAS 9.1 (SAS 
Institute) was used for data management and statistical analyses of the HBV cohort. PROC 
FREQ was used to compute frequencies on individual variables. Statistical significance 
refers to two-sided p values of <0.05. Odds ratios and p values were calculated by using 
conditional logistic regression with PROC LOGISTIC adjusting for HIV-1 status and 
ethnicity.
Rapid amplification of cDNA ends (RACE) and quantitative PCR (qPCR)
Peripheral blood was obtained from healthy donors and lymphocytes were separated using 
lymphocyte separation medium as per manufacturer’s instructions (Lonza). Total RNA was 
extracted from peripheral blood lymphocytes (PBLs; RNeasy Universal kit, Qiagen). Each 
sample was treated with gDNA eliminator to remove genomic DNA. The RNAs were 
quantified using the HT RNA Lab Chip (Caliper, Life Sciences), and all samples had an 
RNA quality score of >8. In order to determine the transcript boundaries, 3’RACE and 5’ 
RACE were performed using 3’ and 5’ Rapid amplification systems (Invitrogen) according 
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to the manufacturer’s instructions. One microgram of RNA was used to initiate first strand 
cDNA synthesis at the poly(A) tail of the mRNA. The 3’ and 5’ ends of CCR5AS were 
amplified using gene specific primers (GSP) and a universal primer (UAP) (sequences 
provided in the list of primers). Amplicons were electrophoresed on 2% agarose gels to 
determine their length, and then they were cloned and sequenced to confirm the specificity 
of amplification.
The mRNA expression level was measured by qPCR. Briefly, reverse transcription was 
performed with 900ng of total RNA using the high capacity RNA to cDNA kit (Applied 
Bioscience) in a volume of 10μl. CCR5 coding region, CCR5 3’UTR, CCR5AS and 
GAPDH transcripts were amplified by SYBR green qPCR using the threshold cycle (CT) 
method54 in either a Viia7 machine (Applied Bioscience) or a Quantstudio 5 machine 
(Applied Biosystems). Each qPCR reaction included 6μl of power SYBR green PCR 
mastermix (Applied Biosystems), 200nM primers that specifically amplified the gene of 
interest or the housekeeping gene (GAPDH), and 2 μl of cDNA (1:20 dilution) in a total 
volume of 12 μl. The genes were amplified using the following conditions: 50°C for 2 
minutes, 95°C for 2 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute. The specificity of primers was tested by melt curve analysis using a dissociation 
step following the qPCR protocol and confirmed by sequencing the amplicons. The primers 
were found to amplify the targeted transcripts specifically and did not cross react with any 
other locus. The average expression levels of the genes were normalized to that of GAPDH 
RNA using the 2-ΔΔCt method54. Oligonucleotide primer sequences are provided in the list 
of primers and probes.
Construction of CCR5 3’UTR and CCR5AS luciferase reporters
The complete 3’UTR fragment of the CCR5 gene was amplified from genomic DNA and 
inserted downstream of the Renilla luciferase gene in the psicheck2 vector.
A 1000 base pair fragment immediately upstream of the transcription start site of CCR5AS 
and the intronic fragment containing the rs2027820A/G polymorphic site were cloned 
upstream and downstream of the firefly luciferase gene, respectively, in a PGL3-basic vector 
(Promega). The vectors were termed intA (rs2027820A) and intG (rs2027820G) as per the 
allele at the polymorphic site. The sequences of the primers used for sequencing are 
provided in the list of primers and probes.
Cell culture, cell transfection and luciferase reporter assays
CCR5 3’UTR—The Hut-78 cell line was maintained in RPMI 1640 (Gibco) medium with 
10% heat inactivated fetal bovine serum (FBS; Atlanta Biologicals). Hut-78 or primary 
CD4+ T cells from donors with rs1015164AG genotype were plated at a density of 0.5×106 
cells/well in a 12 well plate and transfected with 100nM final concentration of either Control 
siRNA or gene-targeting (CCR5AS or Raly) siRNA optimized using TransIT-X2® (Mirus 
Bio LLC) protocol. The cells were incubated for 24 hours in a 37°C CO2 incubator before 
determining mRNA expression or the cell-surface expression of CCR5. Hut-78 cells were 
plated at a density of 0.5×106 cells/well and transfected with 1μg/well of the CCR5 3’UTR 
reporter constructs in the psichek2 vectors using the optimized TransIT-X2® (Mirus Bio 
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LLC) protocol. Transfected Hut-78 cells were incubated for 24 hours at 37°C in a CO2 
incubator. The cells were lysed, and Firefly and Renilla luciferase activity were measured 
using the Dual Luciferase Reporter Assay System (Promega). Renilla luciferase activity was 
normalized relative to Firefly luciferase activity for each transfection. All experiments were 
performed with six replicates in two independent experiments.
CCR5AS—100ng of PGL3 vectors IntA or IntG were transfected into a Lenti-X cell line 
(derivative of 293T cells; Clontech) along with 6ng of Renilla vector. The cells were 
incubated for 24 hours and Firefly and Renilla luciferase activity were measured as 
described above. Firefly luciferase activity was normalized relative to Renilla luciferase 
activity for each transfection. Two independent experiments were performed with 3 
replicates each.
Antibodies and flow cytometry
Bulk PBMCs isolated from whole blood via Ficoll-Paque PLUS (GE Healthcare) were 
stained for expression of CCR5 with the following antibodies (Biolegend): CD3-FITC clone 
UCHT1, CD4-PerCp-Cy5.5 clone OKT4, CCR5-PE-Cy7 clone J418F1, CCR7-APC clone 
G043H7, CD45RA-BV605 clone HI100, and CD45RO-BV785 clone UCHL1. Flow 
cytometry was performed on a BD Fortessa flow cytometer (BD Biosciences) and data were 
analyzed with FlowJo version 10.1.
CCR5 expression on the surface of Hut-78 cell line or CD4+ T cells was analyzed by 
staining with a PE-Cy7 conjugated antibody (Biolegend, clone J418F1), and expression was 
measured using an LSRII flow cytometer (BD Biosciences) or an AccuriC6 flow cytometer 
(BD Biosciences). The histograms were plotted using FlowJo software version 10.
RNA antisense pull down (RAP), polyacrylamide gel electrophoresis (PAGE) and Western 
blot analyses
An RNA antisense pull down protocol was adapted from a previously published method55. 
Hut-78 cells were UV-crosslinked (at 254nm) to capture RNA bound proteins. The cross-
linked cells were lysed in the presence of protease and RNAse inhibitors. 50bp long 
biotinylated antisense oligonucleotide probes tiled across the entire CCR5AS transcript or 
biotinylated scrambled probe were synthesized. Probes were mixed with the lysate and 
hybridized at 37°C for 2–3 hours. RNA-protein complexes were purified with streptavidin 
coated magnetic beads and the bead bound complexes were eluted. Enrichment of CCR5AS 
RNA was analyzed using qPCR. Proteins captured on the beads were separated with Tris-
glycine 4–12% gradient protein gel (Invitrogen) electrophoresis and detected by Coomassie-
blue stain. Western blot was carried out using anti-Raly antibody (Invitrogen) and an anti-
rabitt horse radish peroxidase (HRP) conjugated secondary antibody.
Identification of proteins by nano LC-tandem Mass Spectrometry (nLC-MS/MS)
The gel bands were excised with gel cutting racked tips and digested with trypsin as 
described previously56. Tryptic digests of proteins extracted from the gels (“in-gel” digests), 
were separated with a reversed-phase column using a linear gradient. Eluted peptides were 
subjected to reverse-phase micro-capillary nLC-MS/MS analysis using an Eksigent HPLC 
Kulkarni et al. Page 12
Nat Immunol. Author manuscript; available in PMC 2019 December 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
system (Eksigent) directly interfaced with an Orbitrap LTQ XL mass spectrometer (Thermo 
Fisher). The eluted ions were analyzed by full precursor MS scans acquired with the FT 
Orbitrap analyzer operated at a resolving power of 30,000 (400–2,000 m/z). MS spectrum 
was followed by eight MS/MS spectra, where the eight most abundant multiply charged ions 
were selected for MS/MS sequencing. Raw data were analyzed with Proteome Discoverer 
1.4 (Thermo Fisher; https://www.thermofisher.com/order/catalog/product/
IQLAAEGABSFAKJMAUH) software and searched against the SwissProt database 
restricted to human entries by using the MASCOT http://www.matrixscience.com/help/
seq_db_setup_sprot.html) search engine. The precursor-ion tolerance was 10 ppm and the 
fragment-ion tolerance was 0.8 Da. Enzymatic digestion was specified as trypsin, with up to 
2 missed cleavages allowed.
RNA immuno-precipitation (RIP)
Hut-78 were transfected with a plasmid encoding Raly cDNA with a Myc-tag (Clone 
RC210723, Origene) along with either siCon1 or siLnc1. For RNA immunoprecipitation of 
ribonucleoprotein (RNP) complexes from whole-cell extracts, the transfected cells were 
lysed in 20 mM Tris-HCl at pH 7.5, 100 mM KCl, 5mM MgCl2 and 0.5% NP-40 for 10 min 
on ice and centrifuged at 10,000 RPM for 15 min at 4°C. The supernatants were incubated 
with magnetic beads coated either with IgG or anti-Myc antibodies overnight at 4°C. 
Afterwards, the beads were washed with TBS-T buffer, the complexes were incubated with 
20 units of RNase-free DNase I (15 min at 37°C) and further incubated with 0.1% SDS/0.5 
mg/ml Proteinase K (15min at 55°C) to remove DNA and proteins, respectively. The RNPs 
isolated from the RIP were further assessed by immunoblot blot using an anti-Myc antibody 
(Clone 9E10) and an anti-mouse HRP conjugated secondary antibody for detection of Myc 
tagged proteins and by qPCR for detection of CCR5AS and CCR5 3’UTR.
CCR5 mRNA decay
CCR5 mRNA RNA decay was determined by 5-ethnyluridine (EU) pulse-labeling of RNA 
using the Click-iT Nascent RNA Capture Kit (Invitrogen, Thermo Scientific). Hut-78 cells 
were transfected with siCon1 or siLnc1. Four hours after transfection, the cells were pulsed 
with EU (0.2 mM/1×106/ml). Eighteen hours post-pulsing, the cells were spun down, 
washed with plain RPMI-1640 medium, supplemented with fresh growth medium and 
harvested at one hour intervals for 4 hours. Total RNA was isolated from cells and 
quantitated. The EU-labeled RNA was biotinylated, precipitated, and captured using the 
streptavidin coated magnetic beads as per the manufacturer’s protocol. RNA captured on 
beads was used for cDNA synthesis and qPCR analysis (primer sequences provided in the 
list of primers and probes).
Hut-78 cells were transfected with siCon or siRaly. Sixty hours after transfection, the cells 
were pulsed with EU (0.2 mM/1×106/ml). Eighteen hours post-pulsing, the cells were spun 
down, washed with plain RPMI-1640 medium, supplemented with fresh growth medium, 
and harvested at one hour intervals for 4 hours. Total RNA was isolated from cells and 
quantitated. The EU-labeled RNA was biotinylated, precipitated, and captured using the 
streptavidin coated magnetic beads as per the manufacturer’s protocol. RNA captured on 
beads was used for cDNA synthesis and qPCR analysis.
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HIV-1 constructs and virus production
A Δenv HIV-1 plasmid encoding GFP and GFP-encoding R5-tropic HIV-1 vector derived 
from the NL4–3 molecular clone 57,58,59 was provided by N. Manel and D. Littman (New 
York University, New York, New York, USA). The env gene was derived from BaL HIV-1 
and it is encoded within a vector containing all of the HIV genes60. Viral particles were 
produced by transfecting 293T cells with the respective HIV-1 plasmids and, if applicable, 
with pCG-VSV-G, using TransIT-293 (Mirus) in OptiMEM per the manufacturer’s 
instructions. Supernatants containing infectious viral particles were harvested 48 hours after 
transfection, centrifuged, treated with DNase I (20 U/ml) at room temperature for 1 hour, 
and stored at –80°C.
In vitro infection assays
CD4+ T cells were negatively isolated from frozen peripheral blood lymphocytes with purity 
greater than 95% of all viable lymphocytes. The CD4+ T cells from healthy donors with 
rs1015164AG genotype were transfected with 300nM siRNAs using Mirus transfection 
reagent. Eight hours after transfection, the cells were resuspended in culture medium 
supplemented with 20% fetal calf serum, and human recombinant IL-2 (hrIL-2; 50U/ml). 
Twenty four hours after transfection, CCR5AS expression was assessed by qPCR and cells 
were infected with R5 HIV-1 at 0.01 multiplicity of infection (MOI) for 4 hours at 37°C or 
with VSV-G psuedotyped HIV-1 virus at a tissue culture infective dose (TCID50) of 5000 to 
maintain similar levels of infection between the VSV and R5 viruses as per the previously 
published protocol60. After 2 washes, cells were resuspended in growth medium and plated 
at 5 × 105 cells/well in a 24-well plate. At regular intervals, the cultures were fed by 
removing and replacing one-half of the culture supernatant with fresh growth medium 
supplemented with hrIL-2 and were analyzed after 96 hours by flow cytometric assessment 
of GFP expression.
CD4+ T cells were negatively isolated from frozen peripheral blood lymphocytes were 
resuspended in culture medium supplemented with 20% fetal calf serum, and human 
recombinant IL-2 (hrIL-2; 50U/ml) for 24 hours. CD4+ T cells from healthy donors with 
rs1015164 AA, AG, or GG genotype (N=55) were infected with R5 HIV-1 at 0.01 MOI or 
with VSV-G psuedotyped HIV-1 at TCID50 of 5000 for 4 hours at 37°C. After 2 washes, 
cells were resuspended in growth medium and plated at 5 × 105 cells/well in a 24-well plate. 
At regular intervals, the cultures were fed by removing and replacing one-half of the culture 
supernatant with fresh growth medium supplemented with hrIL-2 and were analyzed after 96 
hours by flow cytometric assessment of GFP expression.
Electrophoretic Mobility Shift Assay
Nuclear extracts prepared from HeLa and Jurkat cell lines via the CellLyticNuCLEAR 
extraction kit (Sigma-Aldrich) were stored at −80°C until use. Lysate from HEK 293 
transfected with recombinant human Atf1 (Creative BioMart) was used as a positive control. 
Double-stranded DNA oligonucleotide probes incorporating the predicted ATF-1 binding 
sequence (Fwd: 5’- GTGAAAGCTTGTTACGTAGGTAACCTTTTGT-3’; Rev: 5’- 
GGACAAAAGGTTACCTACGTAACAAGCTTT-3’) or the mutant sequence (Fwd: 5’- 
GTGAAAGCTTGTTACATAGGTAACCTTTTGT-3’; Rev: 5’- 
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GGACAAAAGGTTACCTATGTAACAAGCTTT-3’) were synthesized and labelled using 
Klenow fragment of DNA polymerase I (Invitrogen) with [α−32P]deoxycytidine 
triphosphate (3000 Ci/mmol; PerkinElmer Life and Analytical Sciences). The core binding 
site for ATF1 is underlined and the rs2027820 variant is bolded. 32P-labeled double stranded 
oligonucleotides were purified using the mini Quick Spin Oligo Columns (Roche). The 
DNA-protein binding reactions were performed in a 20 μl volume containing 10 μg nuclear 
extract, 1 μg poly(dI-DC) (Sigma-Aldrich), 1 μl 32P-labelled oligonucleotide probe (10,000 
cpm) and 1 μL either control nonspecific IgG antibody (mouse IgG, sc-2025, Santa Cruz 
Biotechnology) or Sp1-specific antibody (Clone E-3, Santa Cruz Biotechnology) or ATF1-
specific antibody (clone C41–5.1, Santa Cruz Biotechnology) as described previously61. The 
reactions were then loaded on a 5% polyacrylamide gel and electrophoresed in 0.5x TBE for 
2.5 hours at 120 V. The gel was visualized with autoradiography.
Bioinformatic Analysis of CCR5 and CCR5AS Interaction Sites with Raly protein
In silico prediction of the interaction between the CCR5AS transcript as well as CCR5 
mRNA and the Raly protein was done using a freely available algorithm (http://
service.tartaglialab.com/new_submission/globalscore), which integrates properties of protein 
and RNA structures into overall binding propensity. Global score predicts global and local 
interactions between RBP and lncRNA.
List of primers and probes
qPCR primers—CCR5ASFw TCCTGGTCCCCGTATTGAAT
CCR5ASRev AGGAAGGTATGTGGTGACCA
CCR5Fw GTCCCTTCTGGGCTCACTAT
CCR5Rev CCCTGTCAAGAGTTGACACATTGTA
CCR53’UTRFw GCCTGCCCAGTGCACACAAG
CCR53’UTRRev CCCCCACCCCCATTCAGTCT
GAPDHFw GGTGAAGGTCGGAGTCAACG
GAPDHRev GTTGAGGTCAATGAAGGGGTC
siRNA target sequences—siCon1 TAAGGCTATGAAGAGATACTC
siLnc1 CCCACCCGCUGAUUCAAUATT
siCon2 TCTCGTCGGCTCACGACCTGAAGTA
siLnc2 TCTAATGCGGCCTCTCACCAGTGTT
RACE amplification and sequencing primers—3’RACE GSP1 
CTCACCAGTGTTCGCAGAAA
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UAP GGCCACGCGTCGACTAGTACTTTTTTTTTTTTTTTT
5’RACE GSP1 TCCGGGGACTTCGGCACCAAATG
5’RACE GSP2 TTTCTGCGAACACTGGTGAGAGG
Biotinylated probes for RNA antisense pulldown—AS1 
(BTN)TATTGAATCAGCGGGTGGGTTTCTGCGAACACTGGTGAGAGGCCGCATTA
AS2 
(BTN)ACTGTCATGGCAGGTTCCTGGTCCCCGTATTGAATCAGCGGGTGGGTTTC
AS3 
(BTN)AGTGAGATGCCTTCTGAATATGTGCCCACAAGAAGTTGTGTCTAAGTCTGGT
TCTC
SC (BTN)CCTAAAGGTTAAGTCGCCCTCGCTCG 
TTTCATAGGGTCGAAGCACTGCAAGC
PCR amplification and sequencing for rs1015164A/G—F1 
GTCCCACTTCCTTTCTGTGG
R1 GGCCTGGGTAGGTTTTTAGC
Cloning of CCR5AS upstream region and intron in luciferase vector—
LNC11.2UPMLUIF GATAAACGCGTAAATGGGAGATGATTTTCCCC
LNC11.2UPXHOIF TTATCCTCGAGTCAGAGTGTCACATGCCACAAG
LNC11.2INTBAMHI GATAAGGATCCAATGACAGATTAGATAAAGAAAGTGTGG
LNC11.2INTSALI TTATCGTCGACGGGACAGATTAAATTATCATCAGTC
Reporting Summary
Further information on research design is available in the Life Sciences Reporting Summary 
linked to this areticle linked to this article.
Data availability statement
The data that support the findings of this study are available from the corresponding author 
upon reasonable request.
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Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
The project was supported by NIAID (AI120900; AI140956; S. Kulkarni), HU-CFAR (S. Kulkarni), Cowles 
fellowship (S. Singh), Institutional funds from the Texas Biomedical Research Institute and the Ragon Institute of 
Kulkarni et al. Page 16
Nat Immunol. Author manuscript; available in PMC 2019 December 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
MGH, MIT and Harvard. This project has been funded in whole or in part with federal funds from the Frederick 
National Laboratory, Contract No. HHSN261200800001E. The content of this publication does not necessarily 
reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, 
commercial products, or organizations imply endorsement by the U.S. Government. This Research was supported in 
part by the Intramural Research Program of the NIH, Frederick National Lab, and Center for Cancer Research. See 
extended acknowledgements in Supplementary Information for full details.
References
1. Kopp F & Mendell JT Functional Classification and Experimental Dissection of Long Noncoding 
RNAs. Cell 172, 393–407 (2018). [PubMed: 29373828] 
2. Qiu L et al. Long Non-coding RNAs: Regulators of Viral Infection and the Interferon Antiviral 
Response. Frontiers in microbiology 9, 1621 (2018). [PubMed: 30072977] 
3. Wang P, Xu J, Wang Y & Cao X An interferon-independent lncRNA promotes viral replication by 
modulating cellular metabolism. Science 358, 1051–1055 (2017). [PubMed: 29074580] 
4. Chen YG, Satpathy AT & Chang HY Gene regulation in the immune system by long noncoding 
RNAs. Nat. Immunol 18, 962–972 (2017). [PubMed: 28829444] 
5. Kumar V et al. Human disease-associated genetic variation impacts large intergenic non-coding 
RNA expression. PLoS Genet 9, e1003201 (2013). [PubMed: 23341781] 
6. Ling H et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression 
and chromosomal instability in colon cancer. Genome Res. 23, 1446–1461 (2013). [PubMed: 
23796952] 
7. Castellanos-Rubio A et al. A long noncoding RNA associated with susceptibility to celiac disease. 
Science 352, 91–95 (2016). [PubMed: 27034373] 
8. Kenyan Bacteraemia Study G et al. Polymorphism in a lincRNA Associates with a Doubled Risk of 
Pneumococcal Bacteremia in Kenyan Children. Am. J. Hum. Genet 98, 1092–1100 (2016). 
[PubMed: 27236921] 
9. Berger EA, Murphy PM & Farber JM Chemokine receptors as HIV-1 coreceptors: roles in viral 
entry, tropism, and disease. Annu. Rev. Immunol 17, 657–700 (1999). [PubMed: 10358771] 
10. McLaren PJ & Carrington M The impact of host genetic variation on infection with HIV-1. Nat. 
Immunol 16, 577–583 (2015). [PubMed: 25988890] 
11. Naranbhai V & Carrington M Host genetic variation and HIV disease: from mapping to 
mechanism. Immunogenetics 69, 489–498 (2017). [PubMed: 28695282] 
12. Paxton WA et al. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected 
individuals: association with low expression of CCR5 and high production of beta-chemokines. 
Virology 244, 66–73 (1998). [PubMed: 9581779] 
13. Wu L et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic 
HIV-1, in vitro. J. Exp. Med 185, 1681–1691 (1997). [PubMed: 9151905] 
14. Gonzalez E et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. 
Proc. Natl. Acad. Sci. U. S. A. 96, 12004–12009 (1999). [PubMed: 10518566] 
15. Kawamura T et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated 
by compound CCR5 polymorphisms. Proc. Natl. Acad. Sci. U. S. A 100, 8401–8406 (2003). 
[PubMed: 12815099] 
16. Martin MP et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. 
Science 282, 1907–1911 (1998). [PubMed: 9836644] 
17. Mummidi S et al. Evolution of human and non-human primate CC chemokine receptor 5 gene and 
mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific 
transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the 
pathogenesis of HIV-1 and simian immunodeficiency virus. J. Biol. Chem 275, 18946–18961 
(2000). [PubMed: 10747879] 
18. Thomas SM et al. CCR5 expression and duration of high risk sexual activity among HIV-
seronegative men who have sex with men. AIDS 20, 1879–1883 (2006). [PubMed: 16954729] 
19. Gervaix A et al. Response to treatment and disease progression linked to CD4+ T cell surface CC 
chemokine receptor 5 density in human immunodeficiency virus type 1 vertical infection. J. Infect. 
Dis 185, 1055–1061 (2002). [PubMed: 11930315] 
Kulkarni et al. Page 17
Nat Immunol. Author manuscript; available in PMC 2019 December 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
20. Choudhry V et al. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface 
concentration. Biochem. Biophys. Res. Commun 348, 1107–1115 (2006). [PubMed: 16904645] 
21. Reynes J, Baillat V, Portales P, Clot J & Corbeau P Relationship between CCR5 density and viral 
load after discontinuation of antiretroviral therapy. JAMA 291, 46 (2004). [PubMed: 14709574] 
22. Heredia A et al. CCR5 density levels on primary CD4 T cells impact the replication and 
Enfuvirtide susceptibility of R5 HIV-1. AIDS 21, 1317–1322 (2007). [PubMed: 17545708] 
23. Dean M et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele 
of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS 
Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. 
Science 273, 1856–1862 (1996). [PubMed: 8791590] 
24. Mummidi S et al. Genealogy of the CCR5 locus and chemokine system gene variants associated 
with altered rates of HIV-1 disease progression. Nat. Med 4, 786–793 (1998). [PubMed: 9662369] 
25. Smith MW et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection 
and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS 
Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City 
Cohort (SFCC), ALIVE Study. Science 277, 959–965 (1997). [PubMed: 9252328] 
26. McLaren PJ et al. Polymorphisms of large effect explain the majority of the host genetic 
contribution to variation of HIV-1 virus load. Proceedings of the National Academy of Sciences of 
the United States of America (2015).
27. Sciaranghella G et al. CCR5 Expression Levels in HIV-Uninfected Women Receiving Hormonal 
Contraception. J. Infect. Dis 212, 1397–1401 (2015). [PubMed: 25895986] 
28. Joshi A et al. CCR5 promoter activity correlates with HIV disease progression by regulating CCR5 
cell surface expression and CD4 T cell apoptosis. Sci Rep 7, 232 (2017). [PubMed: 28331180] 
29. Picton AC, Shalekoff S, Paximadis M & Tiemessen CT Marked differences in CCR5 expression 
and activation levels in two South African populations. Immunology 136, 397–407 (2012). 
[PubMed: 22509959] 
30. Zeller T et al. Genetics and beyond--the transcriptome of human monocytes and disease 
susceptibility. PLoS ONE 5, e10693 (2010). [PubMed: 20502693] 
31. Ingolia NT, Lareau LF & Weissman JS Ribosome profiling of mouse embryonic stem cells reveals 
the complexity and dynamics of mammalian proteomes. Cell 147, 789–802 (2011). [PubMed: 
22056041] 
32. Lin MF, Jungreis I & Kellis M PhyloCSF: a comparative genomics method to distinguish protein 
coding and non-coding regions. Bioinformatics 27, i275–282 (2011). [PubMed: 21685081] 
33. Hon CC et al. An atlas of human long non-coding RNAs with accurate 5’ ends. Nature 543, 199–
204 (2017). [PubMed: 28241135] 
34. Guil S & Esteller M Cis-acting noncoding RNAs: friends and foes. Nat Struct Mol Biol 19, 1068–
1075 (2012). [PubMed: 23132386] 
35. Lee B, Sharron M, Montaner LJ, Weissman D & Doms RW Quantification of CD4, CCR5, and 
CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-
derived macrophages. Proc. Natl. Acad. Sci. U. S. A 96, 5215–5220 (1999). [PubMed: 10220446] 
36. Rashid F, Shah A & Shan G Long Non-coding RNAs in the Cytoplasm. Genomics Proteomics 
Bioinformatics 14, 73–80 (2016). [PubMed: 27163185] 
37. Yoon JH et al. LincRNA-p21 suppresses target mRNA translation. Mol. Cell 47, 648–655 (2012). 
[PubMed: 22841487] 
38. Gong C & Maquat LE lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3’ 
UTRs via Alu elements. Nature 470, 284–288 (2011). [PubMed: 21307942] 
39. Kretz M et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. 
Nature 493, 231–235 (2013). [PubMed: 23201690] 
40. Xiao ZD et al. Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy 
metabolism and inhibits renal tumor development. Nat Commun 8, 783 (2017). [PubMed: 
28978906] 
41. Rehfuss RP, Walton KM, Loriaux MM & Goodman RH The cAMP-regulated enhancer-binding 
protein ATF-1 activates transcription in response to cAMP-dependent protein kinase A. J. Biol. 
Chem 266, 18431–18434 (1991). [PubMed: 1655749] 
Kulkarni et al. Page 18
Nat Immunol. Author manuscript; available in PMC 2019 December 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
42. Thio CL et al. Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence 
that CCR5 contributes to viral persistence. J. Virol 81, 441–445 (2007). [PubMed: 17079285] 
43. Glass WG et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. 
Med 203, 35–40 (2006). [PubMed: 16418398] 
44. Kakimi K, Guidotti LG, Koezuka Y & Chisari FV Natural killer T cell activation inhibits hepatitis 
B virus replication in vivo. J. Exp. Med 192, 921–930 (2000). [PubMed: 11015434] 
45. Moreno C et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology 42, 
854–862 (2005). [PubMed: 16175603] 
46. Sun Q, Hao Q & Prasanth KV Nuclear Long Noncoding RNAs: Key Regulators of Gene 
Expression. Trends Genet. 34, 142–157 (2018). [PubMed: 29249332] 
47. Noh JH, Kim KM, McClusky WG, Abdelmohsen K & Gorospe M Cytoplasmic functions of long 
noncoding RNAs. Wiley Interdiscip Rev RNA 9, e1471 (2018). [PubMed: 29516680] 
48. Maurano MT et al. Systematic localization of common disease-associated variation in regulatory 
DNA. Science 337, 1190–1195 (2012). [PubMed: 22955828] 
49. Degner JF et al. DNase I sensitivity QTLs are a major determinant of human expression variation. 
Nature 482, 390–394 (2012). [PubMed: 22307276] 
50. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human 
genome. Nature 489, 57–74 (2012). [PubMed: 22955616] 
Kulkarni et al. Page 19
Nat Immunol. Author manuscript; available in PMC 2019 December 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1. rs1015164 A/G variation associates with HIV-1 viral load and CD4 T-cell counts across 
distinct populations.
HIV-infected subjects followed prospectively were grouped according to rs1015164 
genotype (GG and GA+AA). VL and CD4+ T cell counts are plotted against time following 
seroconversion or date of enrollment (censored at ~ 5 years). HIV longitudinal viral load is 
shown for a, African American (n = 992, AA+AG = 135, GG = 857); and b, Hispanics (n = 
331, AA+AG = 142, GG = 189). Longitudinal CD4+ T cell counts are shown for c, African 
American (n = 918, AA+AG = 125, GG = 793); and d, Hispanics (n = 301, AA+AG = 128, 
GG = 173). The lines are best fit (LOWESS lines) to unadjusted VL or CD4 counts. 
Analysis of the log10 transformed HIV VL and CD4+ T-cell count at each timepoint was 
performed using the lmer function in R. We allowed for random effects due to the time post 
enrolment. Likelihood ratio p-values using the ANOVA function in R were calculated to 
compare nested models fit under a maximum-likelihood scenario.
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Fig. 2. rs1015164A/G variation marks differential expression of CCR5AS and CCR5.
a, Schematic representation of the RP11–24-11.2 gene that encodes CCR5AS and the 
position of rs1015164. b, Endogenous CCR5AS expression levels were estimated in total 
RNA from peripheral blood lymphocytes (PBL) (n = 119, rs1015164 AA=12, AG=51, GG= 
56) by qPCR assay. The mean ±SE are depicted as horizontal and vertical bars for each 
group, respectively. Non-parametric Wilcoxon-Mann-Whitney tests were used for statistical 
comparisons and two tailed p values are indicated. c, CCR5AS levels in total RNA from 
CD4+ T cells were estimated from healthy donors (n=55; AA=5, AG=28, GG= 22). 
Statistics are as described in (b). d, PBMCs isolated from whole blood of donors without 
CCR5Δ32 (n=37; AA=10, AG=16, GG=11) were stained for CD3, CD4, CCR5, CCR7, 
CD45RA, and CD45RO, and the geometric mean fluorescence intensity (MFI) was 
measured for CCR5+ cells within bulk CD4+ T cells, bulk memory CD4+ T cells (CD45RO
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+CD45RA-), central effector memory (CEM; CCR7+) CD4+ T cells, and effector memory 
CD4+ T cells (EM; CCR7-). The mean ±SE are depicted as horizontal and vertical bars for 
each group, respectively. Statistical significance was determined by Mann-Whitney tests.
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Fig. 3. CCR5AS enhances CCR5 mRNA and cell surface expression.
The Pearson’s correlation coefficient was used to determine correlation between expression 
levels of CCR5AS and CCR5 mRNA levels in a, CD4+ T cells isolated from PBLs of 
normal donors (n = 55; r=0.42, p=0.0001); b, memory CD4+ T cells isolated from PBLs of 
normal donors (n = 24; r=0.72, p=0.0001); c, monocytes isolated from PBLs of normal 
donors (n = 16; r=0.82, p=0.0001). d, Peripheral blood CD4+ T cells from healthy donors (n 
= 6) were transfected with 300nm siRNA targeting CCR5AS (siLnc1) or a control siRNA 
(siCon1) and CCR5 mRNA was measured 24 hours post-transfection. The mean ±SE are 
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depicted as horizontal and vertical bars for each group, respectively. Paired t test was used 
for statistical comparisons and two tailed p value is indicated. e, Cell surface expression of 
CCR5 was measured 24 hours after siRNA transfection (n = 6). A representative histogram 
for one of 6 donors tested is shown. Red and blue curves depict CCR5 cell surface 
expression of siLnc1 and siCon1 transfected cells, respectively. The open black curve 
depicts isotype control. Fold change in expression levels was calculated as the ratio of MFI 
of CCR5 vs isotype control. The mean ±SE (n = 6) are depicted as horizontal and vertical 
bars for each group, respectively. Paired t test was used for statistical comparisons and two 
tailed p value is indicated. f, CD4+ T cells from healthy donors (n = 6) were transfected with 
in vitro transcribed CCR5AS short form [CCR5AS(S)] or scrambled RNA control 
(ConRNA). CCR5 mRNA was measured 24 hours post-transfection. The mean ±SE are 
depicted as horizontal and vertical bars for each group, respectively. Statistics are as 
described in (e). g, Cell surface expression of CCR5 was measured 24 hours after CCR5AS 
lncRNA transfection. A histogram of one of 6 comparable experiments performed is shown. 
Red and blue curves depict CCR5 cell surface expression on CCR5AS(S) and ConRNA 
transfected cells, respectively. The gray curve depicts isotype controls. Fold change in 
expression levels was calculated as the ratio of MFI of CCR5 vs isotype control. The mean 
±SE (n = 6) are depicted as horizontal and vertical bars for each group, respectively. 
Statistics are as described in (e).
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Fig. 4. CCR5AS binds Raly.
a, RNA antisense pulldown of endogenous CCR5AS was carried out using a biotinylated 
antisense probe for specific pulldown of CCR5AS (AS) or the scrambled control sequence 
(SC). The mean ±SE (n = 6) are depicted as horizontal and vertical bars for each group, 
respectively (n=3), Student’s t test was used for statistical analysis and two tailed p value is 
indicated. b, Coomassie blue stained PAGE gel separating the RBPs that were pulled down 
with SC, AS, or Avidin beads in the absence of any labeled RNA (beads). A distinct protein 
band, which appeared only in the AS lane (Band 2) and proteins of corresponding molecular 
weight in the SC lane (Band 1) and the beads only lane (Band 3) were excised and analyzed 
by MS. The blot is derived from a single experiment. c, Raly was identified by LC-MS/MS 
in the RBPs pulled down using the AS probe (Band 2), and no RBPs were detected in Band 
1 from the SC lane or Band 3 from the beads only control. d, A Myc-tagged Raly protein 
sequence was transfected into Hut-78 cells. The c-Myc tagged protein was 
immunoprecipitated using anti-Myc antibody coated magnetic beads. The protein bound 
RNA was analyzed by qPCR. Endogenous CCR5AS was enriched significantly in the Raly 
Myc-pulldown (Myc-IP) as compared to IgG coated beads (IgG-IP). The mean ±SE (n = 3) 
are depicted as horizontal and vertical bars for each group, respectively. Student’s t test was 
used for statistical comparison and two tailed p value is indicated.
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Fig. 5. Raly regulates CCR5 expression.
a, The Hut-78 cell line was transfected with either control siRNA (siCon) or Raly siRNA 
(siRaly). Cells were harvested at 48h and 72h post-transfection. CCR5 mRNA expression 
was upregulated after 72h in the siRaly-treated cell lines. The mean ±SE (n = 3) are depicted 
as horizontal and vertical bars for each group, respectively. Non-parametric t test was used 
for statistical comparisons and a two tailed p value is indicated. b, CCR5 surface expression 
was upregulated after 72h in the siRaly treated cells (red curve) as compared to the siCon 
treated cells (blue curve). The gray curve indicates isotype control. The histogram is 
representative of one of the three experiments. The mean ±SE (n=3) are depicted as 
horizontal and vertical bars for each group, respectively. Paired t test was used for statistical 
comparisons and two tailed p value is indicated. c, In silico prediction of the interaction 
between the CCR5 transcript and the Raly protein was done using a freely available 
algorithm (http://service.tartaglialab.com/newsubmission/globalscore), which integrates 
properties of protein and RNA structures into overall binding propensity. The interaction 
score predicts global and local interactions between RBP and lncRNA. A high interaction 
score (≈3) predicts a strong interaction between Raly protein and CCR5 transcript in the 
3’UTR. d, CCR5 3’UTR was cloned downstream of Renilla luciferase into a dual luciferase 
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reporter psicheck2 vector. Hut-78 cells were transfected with either the non-targeting siCon 
or siRaly. Seventy-two hours after siRNA transfection, the CCR5 3’UTR luciferase 
constructs were transfected into siCon or siRaly transfected Hut-78 cells. Twenty four hours 
after transfection of the luciferase constructs, the cells were lysed and luciferase activity was 
measured. Renilla and firefly luciferase activity were estimated by dual luciferase assays and 
presented as the normalized ratio of Renilla vs Firefly luciferase activity. The data represent 
six replicates in each group from two independent experiments. The mean ±SE are depicted 
as horizontal and vertical bars for each group, respectively. Non-parametric Wilcoxon-
Mann-Whitney tests were used for statistical comparisons and two tailed p value is 
indicated.
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Fig. 6. CCR5AS inhibits binding of Raly to CCR5 3’UTR.
a, Hut-78 cells were transfected with a vector encoding Myc-tagged Raly protein along with 
either Control siRNA (siCon1) or LncRNA siRNA (siLnc1). Cells were lysed and RNA 
immunoprecipitation was carried out using anti-Myc antibody or control IgG. Fold 
enrichment of CCR5 3’UTR in the pulldown, as determined using qPCR, was higher in the 
absence of CCR5AS (siLnc1 treated cells) as compared to the control (siCon1). Mean ± SE 
(n=3) are presented as vertical columns with error bars. Statistical significance was 
determined using non-parametric t test and two tailed p values are indicated between the 
comparison groups. b, Hut-78 cells were transfected with either a non-targeting siCon1 or 
siLnc1, along with the CCR5 3’UTR luciferase construct. Twenty-four hours after 
transfection, the cells were lysed and luciferase activity was measured. Silencing of 
CCR5AS reduces the expression of the CCR5 3’UTR luciferase construct. Renilla and 
firefly luciferase activity were estimated by dual luciferase assays and presented as the 
normalized ratio of Renilla vs Firefly luciferase activity. The data represent six replicates in 
each group from two independent experiments. The mean ±SE are depicted as horizontal 
and vertical bars for each group, respectively. Non-parametric Wilcoxon-Mann-Whitney 
tests were used for statistical comparisons and two tailed p values are indicated. c, 
Schematic representation of a model proposing CCR5AS interference with binding of Raly 
to CCR5 3’UTR.
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Fig. 7. CCR5AS expression levels associate with susceptibility to CCR5-dependent HIV infection.
a, Peripheral blood CD4+ T cells from 8 unrelated HIV negative donors, all with the 
rs1015164AG genotype, were transfected with control siRNA (siCon1) or CCR5AS siRNA 
(siLnc1). Twenty-four hours post transfection, the cells were infected with either VSV-G 
pseudotyped HIV virus encoding GFP or a CCR5-tropic HIV virus encoding GFP, and 
percent GFP expressing cells was measured after 96 hours. Fold change in % HIV+ cells was 
calculated as a ratio of HIV+ cells in siLnc1 transfected cells vs HIV+ cells in siCon1 
transfected cells. The siRNA mediated silencing of CCR5AS led to 25–50% reduction in the 
proportion of GFP+ T cells in the cultures infected with the CCR5-tropic virus, but the 
downregulation of CCR5AS did not affect the proportion of GFP+ cells in the cultures 
infected with VSV-G pseudotyped vector. The mean ±SE are depicted as horizontal and 
vertical bars for each group. Statistical significance was determined using non-parametric t 
test and two tailed p value is indicated. Each dot represents one donor (n = 8 for each viral 
infection). b, Peripheral blood CD4+ T cells from 55 unrelated HIV negative donors grouped 
according to rs1015164 genotype (AA=5, AG=19, GG=31) were infected with either VSV-G 
pseudotyped HIV virus encoding GFP or a CCR5-tropic HIV virus encoding GFP, and 
percent GFP expressing cells was measured after 96 hours. The mean ±SE are depicted as 
horizontal and vertical bars for each group. Statistical significance was determined using a 
non-parametric t test and two tailed p value is indicated. Each dot represents one donor (n = 
55 for each viral infection) and red dots represent donors with rs1015164AA genotype.
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Fig. 8. ATF1 binds rs2027820G more strongly than rs2027820A.
a, An electrophoretic mobility shift assay (EMSA) was performed with 32P-labelled 
oligonucleotides containing the core binding sequence for ATF1 containing the A or G 
variant of rs2027820. Nuclear extracts of recombinant human ATF1-transfected HEK 293, 
or untransfected HeLa or Jurkat cells were incubated with each of the oligonucleotides 
(indicated as A or G) in the presence of a control antibody (Ctl for ATF1-transfected HEK 
293 extracts was specific for Sp1; Ctl for HeLa and Jurkat extracts was nonspecific IgG) or 
ATF1-specific antibody (ATF1). The presence of a shift (marked Atf1) indicates that the 
oligonucleotide binds a protein contained in the corresponding nuclear extract. A supershift 
is observed when an anti-ATF1 antibody is added, but not when Sp1 antibody or control IgG 
is added. A single experiment was performed. b, A fragment of 1000 base pairs immediately 
upstream of the transcription start site of CCR5AS, and a 500 base pair intronic fragment 
containing the rs2027820A/G polymorphic site were cloned upstream and downstream of 
the firefly luciferase gene, respectively, in a PGL3-basic vector. The firefly luciferase 
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constructs with basic vector (no promoter), control vector (SV40 promoter), IntA 
(rs2027820A), and IntG (rs rs2027820G) were transfected along with Renilla luciferase 
encoding vector in a 293T derivative cell line (Lenti-X). c, Luciferase activity was measured 
24 hours post-transfection and relative activity of Firefly luciferase normalized to Renilla 
was determined as relative light units (RLU). The IntG vector showed significantly higher 
luciferase activity as compared to the IntA vector. The data represent three replicates in each 
group from two independent experiments experiments. The mean ±SE are depicted as 
horizontal and vertical bars for each group, respectively. Statistical significance was 
determined using non-parametric t test and two tailed p value is indicated.
Kulkarni et al. Page 31
Nat Immunol. Author manuscript; available in PMC 2019 December 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
